Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: A retrospective cohort study

BMC Public Health

Volumn 14, Issue 1, 2014, Pages

  Doe Simkins, Maya ^a   Quinn, Emily ^b   Xuan, Ziming ^b   Sorensen Alawad, Amy ^a   Hackman, Holly ^c   Ozonoff, Al ^d,e   Walley, Alexander Y ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

^c MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bystander naloxone; Opioids; Overdose; People who use drugs; Rescue

Indexed keywords

DIAMORPHINE; NALOXONE; NARCOTIC ANTAGONIST;

ADULT; BREATHING; COMPLICATION; DRUG OVERDOSE; DRUG USE; FEMALE; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HUMAN; MALE; MIDDLE AGED; OPIATE ADDICTION; RETROSPECTIVE STUDY; UNITED STATES; YOUNG ADULT;

ADULT; DRUG OVERDOSE; DRUG USERS; FEMALE; HEALTH EDUCATION; HEALTH PERSONNEL; HEROIN; HUMANS; MALE; MASSACHUSETTS; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RESPIRATION; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84899704480     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-14-297     Document Type: Article

References (56)

1. Vital signs: overdoses of prescription opioid pain relievers and other drugs among women-United States, 1999-2010. Centers for Disease Control and Prevention (CDC), MMWR Morb Mortal Wkly Rep 2013 62 26 537 542 23820967
2. National vital statistics reports: deaths: final data for 2009. Centers for Disease Control and Prevention (CDC), Natl Vital Stat Rep 2011 60 3 81 82
3. 2008 death report. Massachusetts Department of Public Health, http://www.mass.gov/eohhs/docs/dph/research-epi/death-report-08.pdf
4. Elevated overdose mortality rates among First Nations individuals in a Canadian setting: a population-based analysis. Milloy MJ, Wood E, Reading C, Kane D, Montaner J, Kerr T, Addiction 2010 105 11 1962 1970 10.1111/j.1360-0443. 2010.03077.x 20825372
5. Development and implementation of an opioid overdose prevention and response program in Toronto, Ontario. Leece PN, Hopkins S, Marshall C, Orkin A, Gassanov MA, Shahin RM, Can J Public Health 2013 104 3 200 e204 23823882
6. Annual report 2011: the state of the drugs problem in Europe. European Monitoring Centre for Drugs and Drug Addiction, Luxembourg: Publications Office of the European Union 2011 87 91
7. Overdose: A Major Cause of Preventable Death in Central and Eastern Europe in Central Asia: recommendations and overview of the situation in Latvia, Kyrgyzstan, Romania, Russia and Tajikistan. Coffin P, Eurasian Harm Reduction Network (EHRN) 2008 1 78
8. Mortality and HIV transmission among male Vietnamese injection drug users. Quan VM, Minh NL, Ha TV, Ngoc NP, Vu PT, Celentano DD, Mo TT, Go VF, Addiction 2011 106 3 583 589 10.1111/j.1360-0443.2010.03175.x 21054619
9. Australian Drug Trends 2010. Findings from the Illicit Drug Reporting System (IDRS). Stafford J, Burns L, Aust Drug Trend Ser 2011 55
10. Legal aspects of providing naloxone to heroin users in the United States. Burris S, Norland J, Edlin B, Int J Drug Policy 2001 12 3 237 248 10.1016/S0955-3959(01)00080-9
11. A response to the opioid overdose epidemic: naloxone nasal spray. Wermeling DP, Drug Deliv Transl Res 2013 3 1 63 74 10.1007/s13346-012-0092-0 23734342
12. Opioid harm reduction strategies: focus on expanded access to intranasal naloxone. Wermeling DP, Pharmacotherapy 2010 30 7 627 631 10.1592/phco.30.7.627 20575626
13. Project Lazarus: community-based overdose prevention in rural North Carolina. Albert S, Brason FW II, Sanford CK, Dasgupta N, Graham J, Lovette B, Pain Med 2011 12 Suppl 2 77 S85 21668761
14. The feasibility of pharmacy-based naloxone distribution interventions: a qualitative study with injection drug users and pharmacy staff in Rhode Island. Zaller ND, Yokell MA, Green TC, Gaggin J, Case P, Subst Use Misuse 2013 48 8 590 599 10.3109/10826084.2013.793355 23750660
15. Take-home naloxone to reduce heroin death. Baca CT, Grant KJ, Addiction 2005 100 12 1823 1831 10.1111/j.1360-0443.2005.01259.x 16367983
16. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH, J Urban Health 2011 88 6 1020 1030 10.1007/s11524-011-9600-7 21773877
17. Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. Dettmer K, Saunders B, Strang J, BMJ 2001 322 7291 895 896 10.1136/bmj.322.7291.895 11302902
18. Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Doe-Simkins M, Walley AY, Epstein A, Moyer P, Am J Public Health 2009 99 5 788 791 10.2105/AJPH.2008.146647 19363214
19. Overdose prevention and naloxone prescription for opioid users in San Francisco. Enteen L, Bauer J, McLean R, Wheeler E, Huriaux E, Kral AH, Bamberger JD, J Urban Health 2010 87 6 931 941 10.1007/s11524-010-9495-8 20967505
20. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. Green TC, Heimer R, Grau LE, Addiction 2008 103 6 979 989 10.1111/j.1360-0443.2008.02182.x 18422830
21. Injection drug users trained by overdose prevention programs: Responses to witnessed overdoses. Lankenau SE, Wagner KD, Silva K, Kecojevic A, Iverson E, McNeely M, Kral AH, J Community Health 2013 38 1 133 141 10.1007/s10900-012- 9591-7 22847602
22. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S, J Addict Dis 2006 25 3 89 96 10.1300/J069v25n03-11
23. Evaluation of a naloxone distribution and administration program in New York City. Piper TM, Stancliff S, Rudenstine S, Sherman S, Nandi V, Clear A, Galea S, Subst Use Misuse 2008 43 7 858 870 10.1080/10826080701801261 18570021
24. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. Seal KH, Thawley R, Gee L, Bamberger J, Kral AH, Ciccarone D, Downing M, Edlin BR, J Urban Health 2005 82 2 303 311 10.1093/jurban/jti053 15872192
25. Prescription naloxone: a novel approach to heroin overdose prevention. Sporer KA, Kral AH, Ann Emerg Med 2007 49 2 172 177 10.1016/j.annemergmed.2006. 05.025 17141138
26. Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. Wagner KD, Valente TW, Casanova M, Partovi SM, Mendenhall BM, Hundley JH, Gonzalez M, Unger JB, Int J Drug Policy 2010 21 3 186 193 10.1016/j.drugpo.2009.01.003 19268564
27. Community-based opioid overdose prevention programs providing naloxone-United States, 2010. Centers for Disease Control and Prevention (CDC), MMWR Morb Mortal Wkly Rep 2012 61 101 105 22337174
28. Opioid overdose: preventing and reducing opioid overdose mortality. http://www.unodc.org/docs/treatment/overdose.pdf
29. Comprehensive HIV prevention for people who inject drugs, revised guidance. http://www.pepfar.gov/documents/organization/144970.pdf
30. Preventing overdose through education and naloxone distribution. http://www.apha.org/advocacy/policy/policysearch/default.htm?id=1443
31. Expanded access to opioid overdose intervention: research, practice, and policy needs. Compton WM, Volkow ND, Throckmorton DC, Lurie P, Ann Intern Med 2013 158 1 65 66 10.7326/0003-4819-158-1-201301010-00013 23277902
32. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, Ruiz S, Ozonoff A, BMJ 2013 346 174 10.1136/bmj.f174 23372174
33. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Coffin PO, Sullivan SD, Ann Intern Med 2013 158 1 1 9 10.7326/0003-4819-158-1-201301010-00003 23277895
34. Responsible management and use of a personal take-home naloxone supply: a pilot project. McAuley A, Lindsay G, Woods M, Louttit D, Drugs Educ Prev Policy 2010 17 4 388 199 10.3109/09687630802530712
35. Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Strang J, Manning V, Mayet S, Best D, Titherington E, Santana L, Offor E, Semmler C, Addiction 2008 103 10 1648 1657 10.1111/j.1360-0443.2008. 02314.x 18821875
36. Evaluation of the staying alive programme: training injection drug users to properly administer naloxone and save lives. Tobin KE, Sherman SG, Beilenson P, Welsh C, Latkin CA, Int J Drug Policy 2009 20 2 131 136 10.1016/j.drugpo. 2008.03.002 18434126
37. Expanded access to naloxone: options for critical response to the epidemic of opioid overdose mortality. Kim D, Irwin KS, Khoshnood K, Am J Public Health 2009 99 3 402 407 10.2105/AJPH.2008.136937 19150908
38. Preventing opiate overdose deaths: examining objections to take-home naloxone. Bazazi AR, Zaller ND, Fu JJ, Rich JD, J Health Care Poor Underserved 2010 21 4 1108 1113 21099064
39. Naloxone-for intoxications with intravenous heroin and heroin mixtures-harmless or hazardous? A prospective clinical study. Osterwalder JJ, J Toxicol Clin Toxicol 1996 34 4 409 416 10.3109/15563659609013811 8699555
40. Take home naloxone for opiate addicts. Apparent advantages may be balanced by hidden harms. Ashworth AJ, Kidd A, BMJ 2001 323 7318 935
41. Emergency antidote, direct to addicts. Hurley D, http://www.nytimes.com/ 2007/12/11/science/11hero.html?pagewanted=print
42. Overdose rescue kits save lives. Knox R, http://www.npr.org/templates/ story/story.php?storyId=17578955
43. Take home naloxone for opiate addicts. Big conclusions are drawn from little evidence. Mountain D, BMJ 2001 323 7318 934 author reply 935 10.1136/bmj.323.7318.934
44. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area. Seal KH, Downing M, Kral AH, Singleton-Banks S, Hammond JP, Lorvick J, Ciccarone D, Edlin BR, J Urban Health 2003 80 2 291 301 10.1093/jurban/jtg032 12791805
45. Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City. Galea S, Worthington N, Piper TM, Nandi VV, Curtis M, Rosenthal DM, Addict Behav 2006 31 5 907 912 10.1016/j.addbeh.2005.07.020 16139434
46. Overdose prevention pilot core competencies. http://www.mass.gov/eohhs/ docs/dph/substance-abuse/core-competencies-for-naloxone-pilot-participants.pdf
47. Opioid overdose prevention with intranasal naloxone among people who take methadone. Walley AY, Doe-Simkins M, Quinn E, Pierce C, Xuan Z, Ozonoff A, J Subst Abuse Treat 2013 44 2 241 247 10.1016/j.jsat.2012.07.004 22980450
48. "The life they save may be mine": diffusion of overdose prevention information from a city sponsored programme. Sherman SG, Gann DS, Tobin KE, Latkin CA, Welsh C, Bielenson P, Int J Drug Policy 2008 [Epub ahead of print]
49. Brief overdose education can significantly increase accurate recognition of opioid overdose among heroin users. Jones JD, Roux P, Stancliff S, Matthews W, Comer SD, Int J Drug Policy 2014 25 1 166 170 10.1016/j.drugpo.2013.05.006 23773683
50. Can we prevent drug related deaths by training opioid users to recognise and manage overdoses? Gaston RL, Best D, Manning V, Day E, Harm Reduct J 2009 6 26-7517-6-26
51. Role of naloxone in opioid overdose fatality prevention; request for comments; public workshop. http://www.fda.gov/drugs/newsEvents/ucm277119.htm
52. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999-2009. Calcaterra S, Glanz J, Binswanger IA, Drug Alcohol Depend 2013 131 3 263 270 10.1016/j.drugalcdep.2012. 11.018 23294765
53. Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2009: National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. (SMA) 11-4659, DAWN Series D-35 Rockville, MD: Substance Abuse and Mental Health Services Administration 2011
54. Borderline personality disorder, antisocial personality disorder and risk-taking among heroin users: findings from the Australian Treatment Outcome Study (ATOS). Darke S, Williamson A, Ross J, Teesson M, Lynskey M, Drug Alcohol Depend 2004 74 1 77 83 10.1016/j.drugalcdep.2003.12.002 15072810
55. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. Strang J, McCambridge J, Best D, Beswick T, Bearn J, Rees S, Gossop M, BMJ 2003 326 7396 959 960 10.1136/bmj.326.7396.959 12727768
56. Effect of abuse-deterrent formulation of OxyContin. Cicero TJ, Ellis MS, Surratt HL, N Engl J Med 2012 367 2 187 189 10.1056/NEJMc1204141 22784140